116 related articles for article (PubMed ID: 9622078)
1. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells.
Sun XY; Plouzek CA; Henry JP; Wang TT; Phang JM
Cancer Res; 1998 Jun; 58(11):2379-84. PubMed ID: 9622078
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase.
Gupta S; Ahmad N; Mohan RR; Husain MM; Mukhtar H
Cancer Res; 1999 May; 59(9):2115-20. PubMed ID: 10232597
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts.
Rice L; Samedi VG; Medrano TA; Sweeney CA; Baker HV; Stenstrom A; Furman J; Shiverick KT
Prostate; 2002 Aug; 52(3):201-12. PubMed ID: 12111696
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
6. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells.
Davis JN; Kucuk O; Sarkar FH
Mol Carcinog; 2002 Jun; 34(2):91-101. PubMed ID: 12112315
[TBL] [Abstract][Full Text] [Related]
7. Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: identification of novel targets.
Takahashi Y; Lavigne JA; Hursting SD; Chandramouli GV; Perkins SN; Barrett JC; Wang TT
Mol Carcinog; 2004 Oct; 41(2):108-119. PubMed ID: 15378649
[TBL] [Abstract][Full Text] [Related]
8. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
[TBL] [Abstract][Full Text] [Related]
9. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells.
Zhang J; Hsu B A JC; Kinseth B A MA; Bjeldanes LF; Firestone GL
Cancer; 2003 Dec; 98(11):2511-20. PubMed ID: 14635088
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
12. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcitriol on prostate-specific antigen in vitro and in humans.
Beer TM; Garzotto M; Park B; Mori M; Myrthue A; Janeba N; Sauer D; Eilers K
Clin Cancer Res; 2006 May; 12(9):2812-6. PubMed ID: 16675575
[TBL] [Abstract][Full Text] [Related]
14. Androgen UDP-glucuronyl transferase activity is found primarily in liver in the rat.
Pirog EC; Clark RV; Collins DC
J Androl; 1993; 14(1):2-8. PubMed ID: 8473234
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17. Sex steroid hormone metabolism and prostate cancer.
Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
20. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
